Ai Miyamoto

Ai Miyamoto

Auto-generated profile, based on publicly available information

Ai Miyamoto

Graduate School of Interdisciplinary Science and Engineering in Health Systems Okayama University Okayama Japan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2025 in Cancer Research
Verified
Journal Article
Closed access
TNToshifumi Ninomiya
Toshifumi Ninomiya
NKNaoya Kemmotsu
Naoya Kemmotsu
FMFumiaki Mukohara
Fumiaki Mukohara
MMMasaki Magari
Masaki Magari
AMAi Miyamoto
Ai Miyamoto
YTYosuke Togashi
Yosuke Togashi
Brain metastasis is a poor prognostic factor in patients with cancer. Despite showing efficacy in many extracranial tumors, immunotherapy with anti–PD-1 mAb or anti–CTLA4 mAb seems to be less effective against intracranial tumors. Promisingly, recent clinical studies have reported that combination therapy with anti–PD-1 and anti–CTLA4 mAbs has a potent antitumor effect on brain metastasis, highlighting the need to elucidate the detailed mechanisms controlling the intracranial tumor microenvironment (TME) to develop effective immunotherapeutic strategies. In this study, we analyzed the tumor-infiltrating lymphocytes in murine models of brain metastasis that responded to anti–CTLA4 and anti–PD-1 mAbs. Activated CD4+ T follicular helper (TFH) cells with high CTLA4 expression characteristically infiltrated the intracranial TME, which were activated by combination anti–CTLA4 and anti–PD-1 treatment. The loss of TFH cells suppressed the additive effect of CTLA4 blockade on anti–PD-1 mAb. B-cell–activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) produced by abundant myeloid cells, particularly CD80hiCD206lo proinflammatory M1-like macrophages, in the intracranial TME induced B-cell and TFH-cell infiltration and activation. Furthermore, the intracranial TME of patients with non–small cell lung cancer featured TFH- and B-cell infiltration as tertiary lymphoid structures. Together, these findings provide insights into the immune cell cross-talk in the intracranial TME that facilitates an additive antitumor effect of CTLA4 blockade with anti–PD-1 treatment, supporting the potential of a combination immunotherapeutic strategy for brain metastases. Significance: B-cell and CD4+ T follicular helper cell activation via BAFF/APRIL from abundant myeloid cells in the intracranial tumor microenvironment enables a combinatorial effect of CTLA4 and PD-1 blockade in brain metastases.

4 March 2026 in Bioconjugate Chemistry
Verified
Journal Article
Open access
RSRyui Sakaguchi
Ryui Sakaguchi
AMAi Miyamoto
Ai Miyamoto
RKRikako Kutsuma
Rikako Kutsuma
TMTakeru Mori
Takeru Mori
DNDaichi Nakashima
Daichi Nakashima
JFJunichiro Futami
Junichiro Futami
Several autoantigens relevant to the immune system, especially those targeted by autoantibodies induced by antitumor responses, tend to be rich in disordered regions and are prone to aggregation. This inherent instability presents significant challenges for the production, purification, and analysis of autoantigens in laboratory settings. Cysteine-specific cationization can effectively solubilize and purify these challenging proteins, allowing the isolation of full-length water-soluble antigens in their denatured state. The purified antigens enable accurate multiplex autoantibody assays using a suspension Luminex bead array platform. However, well-validated positive control antibodies are essential to ensuring precise clinical diagnosis. In this study, we prepared and characterized a panel of control antibodies by immunizing rabbits with cysteine-specific S-cationized antigens. The resulting antibodies predominantly recognized linear epitopes and were highly effective as quality control reagents in autoantibody array assays. Additionally, these antibodies maintained their ability to bind to their native, unmodified intracellular counterparts, highlighting the usefulness of this approach for producing antibodies against intrinsically disordered proteins. Although a modest immune response against the S-cationized modification site was observed, it remained minimal and did not affect the usefulness of the antibodies for assay validation. We propose this versatile cysteine-specific cationization platform for managing unstable proteins rich in disordered regions, supporting antigen production for diagnostics, and antibody development for research and validation purposes.


17 June 2026
Verified
Other
Open access
TNToshifumi Ninomiya
Toshifumi Ninomiya
NKNaoya Kemmotsu
Naoya Kemmotsu
FMFumiaki Mukohara
Fumiaki Mukohara
MMMasaki Magari
Masaki Magari
AMAi Miyamoto
Ai Miyamoto
YTYosuke Togashi
Yosuke Togashi
Gating strategy for T cells in flow cytometry analysis

17 June 2026
Verified
Other
Open access
TNToshifumi Ninomiya
Toshifumi Ninomiya
NKNaoya Kemmotsu
Naoya Kemmotsu
FMFumiaki Mukohara
Fumiaki Mukohara
MMMasaki Magari
Masaki Magari
AMAi Miyamoto
Ai Miyamoto
YTYosuke Togashi
Yosuke Togashi
Clinical courses and additional in vivo efficacy data

14 March 2025
Verified
Other
Open access
TNToshifumi Ninomiya
Toshifumi Ninomiya
NKNaoya Kemmotsu
Naoya Kemmotsu
FMFumiaki Mukohara
Fumiaki Mukohara
MMMasaki Magari
Masaki Magari
AMAi Miyamoto
Ai Miyamoto
YTYosuke Togashi
Yosuke Togashi
Gating strategy for T cells in flow cytometry analysis